Our Roadmap

2023

Building our first prototypes and replicating existing scientific evidence to validate efficacy and safety for migraine prevention with our own, optimized device.

2024

Large scale randomized clinical trial for our migraine prevention device and optimizing our device for manufacturing and usability.

2025

QMS certification, authority approval for 1st generation professional-use migraine prevention device and clinical trial for 2nd generation at-home device.

2026

Market-launch, roll-out of at-home use device with key clinic partnerships to help migraineurs.

Change is driven by the right team

Our purpose-driven interdisciplinary team brings extensive experience in developing transcranial magnetic stimulation systems from the ground up, mobilizing TMS and bringing it to market, MedTech engineering, regulatory affairs, business development, high performance coil designs, real-time EEG processing and state-of-the-art deep learning technologies. 

Our Advisors

Would you like to get involved with Brightmind.AI?

We are happy to speak with potential research partners, investors, users, neurotech disruptors, journalists… feel free to reach out: